



EUROPEAN SOCIETY
for VIROLOGY



SIV ISV
SOCIETÀ ITALIANA
DI VIROLOGIA
ITALIAN SOCIETY
FOR VIROLOGY



7th. European Seminars in Virology (EuSeV) 2019 Program

FRIDAY 14.06.2019

13:45-14:00

Welcome

Dana Wolf, Gabriella Campadelli-Fiume, Thomas Mertens, Michael Kann
Giorgio Palù

Session on Ethical and technological issues about antiviral vaccine and antibodies development Chair: Giorgio Palù

14:00-14:40

Andrea Grignolio, Cognitive bases for vaccine hesitancy
Medical Humanities & Bioethics, Vita-Salute San Raffaele University, Milan, Italy
grignolio.andrea@hsr.it

14:40-15:20

Rino Rappuoli, Reverse vaccinology 2.0
GSK, Siena, Italy rino.r.rappuoli@gsk.com

15:20-16:00

Mel Kohn, MSD's Investigational Ebola Vaccine
Regional Director of Medical Affairs Lead for Vaccines, MSD. melvin.kohn@msd.com

16:00-16:30

Discussion

16:30-17:30

Selected oral presentations

Matti Sallberg, DNA-based prime-boost active immunotherapy to induce a functional cure in patients with chronic hepatitis B
Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden, Laboratory Medicine, Karolinska University Hospital Huddinge, Stockholm

Francesco Santoro, Human transcriptomic response to vaccination with recombinant VSV expressing Ebola virus Glycoprotein
Laboratory of Molecular Microbiology and Biotechnology (LAMMB), Dept. of Medical Biotechnologies, University of Siena, Italy

Matteo Castelli, HCV/E2 dynamics controls overall sensitivity to neutralization
Laboratory of Microbiology and Virology, Università "Vita-Salute" San Raffaele, Milan, Italy

Francesco Nicoli, Poor responsiveness of naïve CD8+ T-cells from elderly individuals is associated to their altered basal metabolism Sorbonne
Sorbonne Université, INSERM, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France - Department of Chemical and Pharmaceutical Sciences, University of Ferrara, Ferrara, Italy

Dhanik Reshamwala, Novel anti-virals against Enteroviruses
Department of Biological and Environmental Science, Nanoscience Center, University of Jyväskylä, Finland

| | |
|---------------------|--|
| 17:30-18:00 | DISCUSSIONS IN FRONT OF POSTERS |
| 20:00 Dinner | |

| | |
|---|--|
| SATURDAY 15.06.2019 | |
| Regulatory and technological issues about antiviral vaccine and antibodies development | |
| Chair: Thomas Mertens & Gabriella Campadelli Fiume | |
| 09:00-09:40 | Guido Silvestri, Towards an HIV vaccine: recent advances from studies in non-human primates Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, USA, gsilves@emory.edu |
| 09:40-10:20 | Christian Sinzger, CMV-Elite-neutralizing Antibodies Institute of Virology, University of Ulm, Ulm, Germany, christian.sinzger@uniklinik-ulm.de |
| 10:20-11:00 | Gabriella Campadelli Fiume, Viruses as vectors of antigen agnostic vaccine Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy, gabriella.campadelli@unibo.it |
| 11:00-11:30 | Break |
| 11:30-12:10 | Thomas Mertens, The art of vaccine recommendations in the real world Institute of Virology, Ulm University Medical Center, Ulm, Germany, thomas.mertens@uni-ulm.de |
| 12:10-13:30 | Selected oral presentations |
| | Alberto Reale, Oncolytic HSV-1 vectors for in situ vaccination against solid tumours Department of Molecular Medicine, University of Padua |
| | Greta Forlani, HTLV-1 Tax and HBZ oncoproteins expression and subcellular localization in infection and disease progression: implications for immune-based therapeutic approaches Laboratories of General Pathology and Immunology "Giovanna Tosi", Department of Medicine and Surgery, University of Insubria, Varese, Italy |
| | Anna Czarnota, Characterization of anti-hepatitis C neutralizing antibody response after immunization with chimeric hepatitis B/hepatitis C virus like particles. Laboratory of Virus Molecular Biology, Intercollegiate Faculty of Biotechnology of the University of Gdańsk and Medical University of Gdańsk |
| | Nir Paran, Antibody Treatment of Smallpox Vaccine Adverse Events Department of Infectious diseases, Israel Institute for Biological Research (IIBR), Ness-Ziona, Israel |
| | Carlo De Giuli Morghen, A recombinant avipoxvirus expressing the env gene of Zika virus as a novel putative preventive vaccine Catholic University "Our Lady of Good Counsel" Tirana, Albania, Department of Medical Biotechnologies and Translational Medicine, Univ. of Milan, Italy |
| | Salomon Amann, An Orf virus-based platform technology for vaccine development using a modulatory brick system University Tuebingen, Interfaculty Institute for Cell Biology, Department for Immunology, Tuebingen, Germany |
| 13:30-15:00 | Lunch break |
| Development of vaccines and antibodies against viral infection | |

| Chair: Dana Wolf | |
|-------------------------|--|
| 15:00-15:40 | Ali Mirazimi, Development of vaccine against Crimean Congo Hemorrhagic Fever; Past and Future Department of Laboratory Medicine, Karolinska University Hospital and KI, Stockholm, Sweden. Ali.Mirazimi@ki.se |
| 15:40-16:20 | Arnaud Marchant, Maternal and neonatal immunization Institute for Medical Immunology, Université Libre de Bruxelles, Brussels, Belgium, arnaud.marchant@ulb.ac.be |
| 16:20-17:00 | Frédéric Tangy, Vaccines against Ebolavirus and other emerging viruses Viral Genomics and Vaccination Unit, Institut Pasteur, Paris, France, ftangy@pasteur.fr |
| 17:00-17:20 | Break |
| 17:20-18:00 | Florian Klein, HIV-Super-neutralizing Antibodies Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany. florian.klein@uk-koeln.de |
| 18:00-19:00 | Selected oral Presentations |
| | Eberhard Hildt, Development of a new vaccine platform for induction of a robust B- and T-cell response against viral infections Paul-Ehrlich-Institut, Department of Virology, Langen, Germany; German Center for Infection Research (DZIF), Braunschweig |
| | Benjamin Gutjahr, Monoclonal antibodies protect mice in Rift Valley fever challenge model Friedrich-Loeffler-Institut, Institute of Novel and Emerging Infectious Diseases (INNT), Greifswald – Isle of Riems, Germany |
| | Ola Blixt, Efficient identification of immunodominant (glyco-)peptides for type-specific serology and monoclonal antibody developments Department of Chemistry, University of Copenhagen, Frederiksberg C, Denmark |
| | Sofia Appelberg, Protection Against Crimean-Congo Hemorrhagic Fever Virus Infection in Mice After Immunization with DNA Plasmids Coding for Different Viral Proteins Public Health Agency of Sweden, Stockholm |
| | AnnaLucia Tornesello, Humoral immune response to HCV peptides as cancer-progression biomarkers of HCV-infections Istituto Nazionale Tumori – IRCCS Fondazione Pascale, Naples, Italy |
| 20:00 Dinner | |

| SUNDAY 16.06.2019 | |
|---|--|
| Success and failure or antiviral vaccine development | |
| Chair: Michael Kann | |
| 9:00-9:40 | John J. Skehel, Experimental uses and roles in immunity of antibodies that recognize influenza haemagglutinin Francis Crick Institute, London, UK, John.Skehel@crick.ac.uk |
| 09:40-10:20 | Emanuele Montomoli, Present and future of anti-influenza vaccinations Department of Molecular and Developmental Medicine, University of Siena, Italy, Emanuele.montomoli@unisi |
| 10:20-11:00 | Wolfgang Hammerschmidt, EBV-Vaccine Research Unit Gene Vectors, Helmholtz Zentrum München, Germany, hammerschmidt@helmholtz-muenchen.de |

| | |
|---|---|
| 11:00-11:40 | Sergio Abrignani, Why is it too difficult to develop a vaccine against HCV INGM, Milan, Italy, abrignani@ingm.org |
| 11:40-12:20 | Giorgio Palù, Clinically and experimentally adopted vaccines against Flavivirus infections and Dengue Department of Molecular Medicine, University of Padova, Italy, giorgio.palu@unipd.it |
| 12:20 Closing Remarks and Brunch | |
| | |